6-Month Open-Label Safety Study Of PD 0332334 In Elderly Patients With Generalized Anxiety Disorder (GAD)

PHASE3WithdrawnINTERVENTIONAL

Timeline

Start Date

January 31, 2009

Primary Completion Date

February 28, 2009

Study Completion Date

February 28, 2009

Conditions

Generalized Anxiety Disorder

Interventions

DRUG

PD-0332334

Dosage from: 50-100 mg oral capsule Dosage and frequency: 50-350 mg once or twice a day Duration: 6 months

Trial Locations (2)

Pfizer Investigational Site, Orlando

Pfizer Investigational Site, Prairie Village